VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
1.543
+0.008 (0.49%)
At close: Jun 25, 2025, 4:00 PM
1.540
-0.002 (-0.16%)
Pre-market: Jun 26, 2025, 8:40 AM EDT
VivoSim Labs Employees
As of March 31, 2025, VivoSim Labs had 13 total employees, including 5 full-time and 8 part-time employees. The number of employees decreased by 7 or -35.00% compared to the previous year.
Employees
13
Change (1Y)
-7
Growth (1Y)
-35.00%
Revenue / Employee
$11,077
Profits / Employee
-$191,385
Market Cap
4.01M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
VIVS News
- 5 weeks ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 6 weeks ago - VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference - GlobeNewsWire
- 7 weeks ago - VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference - GlobeNewsWire
- 2 months ago - VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - GlobeNewsWire
- 2 months ago - VivoSim to Carry Forward Organovo 3D Bioprinting - GlobeNewsWire
- 3 months ago - Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements - GlobeNewsWire
- 3 months ago - Organovo Provides Business Update - GlobeNewsWire
- 3 months ago - Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company - GlobeNewsWire